Survey of a treatment for congenital thrombotic thrombocytopenic purpura

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study surveys the use of recombinant ADAMTS13 in participants with congenital thrombotic thrombocytopenic purpura (cTTP) in Japan. Participants will receive intravenous injections of recombinant ADAMTS13 according to their clinic's standard practice, while the study will monitor for any side effects and assess the treatment's effectiveness in improving or preventing cTTP over an 18-month period. The study aims to gather data on the safety and efficacy of this treatment without direct involvement from the sponsor in patient care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- All participants with congenital thrombotic thrombocytopenic purpura (cTTP), treated with recombinant ADAMTS13

Exclusion Criteria:

\- None

Where it's running

• Takeda Selected Site
  Tokyo, Tokyo, Japan Recruiting

Study contacts

• Study coordinator: Takeda Contact
• Email: medinfoUS@takeda.com
• Phone: +1-877-825-3327

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• cTTP patients treated with recombinant ADAMTS13: what happened after the early access program

  This study looks at people with congenital TTP who received recombinant ADAMTS13 to see how treatment changes their health before and after use.

  Recruiting Takeda · Cologne, North Rhine-Westphalia and 7 other locations · NCT07429942

• Adzynma in people with congenital TTP: a look at safety and antibody risk

  This study checks whether people with congenital TTP who have already received Adzynma develop neutralizing antibodies against Adzynma within six months of starting treatment.

  Recruiting at 6 sites Takeda · Vienna and 6 other locations · NCT07353099

• Long-term outcomes for people with immune TTP in the French national TMA cohort

  This project uses past medical records to see long-term health outcomes and complications in people in France who had immune thrombotic thrombocytopenic purpura (iTTP).

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07205861

• Understanding the immune response in Thrombotic Thrombocytopenic Purpura

  This study is trying to understand how certain immune cells behave in people with Thrombotic Thrombocytopenic Purpura to see if they can help predict relapses and improve treatment.

  Recruiting University Hospital, Rouen · Rouen · NCT06945861

• Registry for patients with immune-mediated thrombotic thrombocytopenic purpura in Italy

  This study is tracking patients with immune-mediated thrombotic thrombocytopenic purpura in Italy to see how the disease affects them over time and what their treatment outcomes are.

  Recruiting Fondazione Luigi Villa · Milan, MI · NCT06376786

• Registry for patients with Thrombotic Thrombocytopenic Purpura in Turkey

  This study is collecting information from patients with Thrombotic Thrombocytopenic Purpura in Turkey to see how the disease is treated and how it affects their health over time.

  Recruiting Turkish Hematology Association · Ankara · NCT05950750

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.